[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620979":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":10,"locations":28,"responsibleParty":48,"collaborators":50,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":10,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"IRCCS Policlinico S. Donato","OTHER",[8,13,16,19],{"label":9,"type":6,"description":10,"interventionNames":11},"breast cancer",null,[12],"Diagnostic Test: ECG",{"label":14,"type":6,"description":10,"interventionNames":15},"metastatic brest cancer",[12],{"label":17,"type":6,"description":10,"interventionNames":18},"colon cancer",[12],{"label":20,"type":6,"description":10,"interventionNames":21},"metastatic colon cancer",[12],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","ECG","These patients require an ECG to exclude the onset of arrhythmias.",[9,17,14,20],[29],{"facility":30,"status":10,"city":31,"state":10,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"IRCCS Policlinico San donato","Milan","20097","Italy",{"type":35,"coordinates":36},"Point",[37,38],9.18951,45.46427,{"lat":38,"lon":37},[41,46],{"name":42,"role":43,"phone":44,"phoneExt":10,"email":45},"Carlo Pappone, Dr.","CONTACT","0252774260","carlo.pappone@grupposandonato.it",{"name":42,"role":47,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51],{"name":52,"class":6},"IRCCS San Raffaele","100620979",false,"NCT07364656","Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic\n* Patients already receiving first-line therapy with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic\n* Signed informed consent\n\nExclusion Criteria:\n\n* Clinically significant cardiovascular diseases (atrial fibrillation, congestive heart failure, cardiomyopathies, or inherited arrhythmic syndromes)\n* Known autoimmune diseases or immunodeficiencies\n* Use of high-dose immunosuppressive drugs or other experimental treatments that could interfere with the assessment of study endpoints","ALL",{"count":60,"type":61},196,"ESTIMATED","INTERVENTIONAL",[64],"NA","The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.",[67,68,69,70,71],"Brugada Syndrome (BrS)","Breast Cancer Females","Colon Cancer","ECG Abnormalities","Autoantibodies Screening","NOT_YET_RECRUITING","2026-01-16",{"date":75,"type":76},"2026-01-23","ACTUAL",{"date":78,"type":61},"2026-01",{"date":80,"type":61},"2026-12",{"name":5,"class":6},1]